Sunovion Announces Promising Results For New ADHD Drug

Sunovion Pharmaceuticals Inc., an NEC member, recently announced the promising results of their Phase 2/3 study for drug candidate Dasotraline, which showed significant improvement of Attention Deficit Hyperactivity Disorder (AHDH) symptoms in children 6-12 years old.

Dasotraline is a new chemical discovered by Sunovion that inhibits dopamine and norepinephrine reuptake. The drug has an extended half-life that allows it to steadily provide the therapeutic effects over a 24-hour period.  Sunovion is studying the drug to determine its use in treating ADHD in children and adults, as well as Binge Eating Disorder in adults. Upon completion of the current studies and talks with the U.S. Food and Drug Administration (FDA), Sunovion plans to submit a New Drug Application for Dasotraline to treat ADHD in children and adults to the FDA in 2017.

“Sunovion is dedicated to advancing the treatment of serious neuropsychiatric conditions, such as ADHD,” said Antony Loebel, M.D., Sunovion’s Executive Vice President and Chief Medical Officer.

The New England Council congratulates Sunovion on the promising results of the Dasotraline study. Read more in Sunovion’s press release and Pharmaceutical Business Review.

Recently from the Blog

Vertex Releases Findings in Type 1 Diabetes Trial

11/9/2021 | Read Post

Amazon will be Hiring 1,500 Seasonal Workers

11/9/2021 | Read Post

In the News

NEC to Honor Historic All-Female Lineup of 2021 New Englanders of the Year

08/2/2021 | Read Press Release

NEC Board Elects Three New Directors

04/27/2021 | Read Press Release